United Kingdom generic drugs market is anticipated to register growth with an impressive CAGR in the forecast period, 2023-2027. The market growth can be attributed to growing instances of chronic diseases. Rising demands for the prolonged dosages for the treatment for various diseases instances of which is further rising and driving the growth of the United Kingdom generic drugs market in the upcoming five years. Additionally, increasing application of the robotic process automation and expiring branded medicine patents also fuel the growth of the United Kingdom generic drugs market in the future years.
Generic drugs
Expanding Pharmaceutical Industry Promises Market Growth
Pharmaceutical
In 2019, the annual turnover of pharmaceutical goods wholesalers in the UK was over USD63 billion. Imports of pharmaceutical products from other countries have considerably decreased in 2020 valued at USD20,871 million from USD23,458 million in the year 2019. Decreased imports points to increased research and development along with growing inclination of the consumers toward generic drugs, thereby substantially supporting the growth of the United Kingdom generic drugs market in the next five years.
Sedentary Lifestyle Fuels Market Growth
The population in the country is highly inclined to junk food and fast food as a regular consumption along with the increased consumption of alcohol and excessive smoking. The lack of physical workout along with the sedentary lifestyle is the major factor leading to various diseases like obesity, higher blood pressure, diabetes, etc. that may further lead to the chronic diseases like cardiovascular diseases, or cancer. Increasing instances of the diseases and demand for the medicines and other drugs for the treatment drive the growth of the United Kingdom generic drugs market in the upcoming five years.
Although, the population is steadily inclining toward healthier life and losing weight, the demands for the weight loss medicines like Orlistat is increasing and substantiating the growth of the United Kingdom generic drugs market in the next five years. The NHS spent £8,167,383 on Orlistat in 2020 in England. It is the prescription only weight loss aid that is licensed in the country for sale.
Click here to download the sample
Market Segmentation
The United Kingdom generic drugs market is segmented by type, mode of drug delivery, form, source, distribution channel, application, competitional landscape, and regional distribution.
Company Profile
GlaxoSmithKline Plc., Abbott Laboratories Limited, Eli Lilly and Company Limited, Teva UK Limited, Mylan UK Healthcare Limited, Pfizer Limited, Novartis UK Limited, Sun Pharmaceuticals UK Limited
| Attribute | Details |
| Base Year | 2021 |
| Historical Data | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Type · By Mode of Drug Delivery · Form · Source · Distribution Channel · Application |
| Regional scope | London, East Anglia, Southwest, Southeast, Scotland, East Midlands, and Yorkshire & Humberside |
| Key companies profiled | GlaxoSmithKline Plc., Abbott Laboratories Limited, Eli Lilly and Company Limited, Teva UK Limited, Mylan UK Healthcare Limited, Pfizer Limited, Novartis UK Limited, Sun Pharmaceuticals UK Limited |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
